The Chinese regime recently mandated that 50 million doses of COVID-19 vaccines must be administered to people designated as high risk by Feb. 15, 2021—although drug companies have yet to complete testing and the vaccines have yet to be approved by regulators.
Meanwhile, Fosun Pharmaceutical announced that it had ordered 100 million doses of the COVID-19 vaccine developed by German drug company BioNTech, which will arrive in China in 2021. BioNTech has partnered with Pfizer to supply vaccines for the U.S. and EU markets, which were approved by their respective regulators, but the vaccine developed for the China market is still in Phase II trial.
China has five different COVID-19 vaccines under development, according to health authorities.
Currently, all five are still under phase III trial, which is a clinical trial conducted on a large group of people to see whether the drug is efficient or has side effects.
Two of them are developed in collaboration with Chinese state-run research institutes, Academy of Military Medical Sciences and Chinese Academy of Sciences.
Chinese authorities also recently warned that Chinese-manufactured vaccines could bring about side effects, such as headache, fever, vomiting, and diarrhea.
Media reports surfaced that hundreds of Chinese workers overseas were infected with COVID-19 even after receiving China-made vaccines.
50 Million Vaccinations
China’s cabinet-like State Council announced at a press conference on Dec. 19 that it would arrange “high-risk groups” to receive the COVID-19 vaccine.
Those are: people who work in frozen foods logistics, customs border personnel, medical and disease control personnel, workers at farmer’s markets and seafood markets, and public transportation workers.